Smart + Strong.
All Rights Reserved.
Smart + Strong®
is a registered trademark of CDM Publishing, LLC.
PrEP plus HIV screening every three months would lead to fewer new cases, longer life expectancy and lower HIV-associated costs.
The Biden initiative marks a turning point in a long-fought battle to control ever-rising drug prices.
In the 1980s, AZT was labeled the most expensive drug in history at $8,000 annually. Now, scores of drugs cost more than $50,000 a year.
Internal documents show Gilead held off on developing new therapies, such as Descovy, a potentially less toxic version of Truvada.
The $3.6 billion antitrust court case cleared Gilead Sciences and Teva of delaying the release of generic Truvada and other HIV meds.
While expensive new drugs are developed, thousands of people can’t get a drug like cisplatin that costs as little as $6 a dose.
Yes! The Mark Cuban Cost Plus Drug Company sells cheaper generic drugs for diabetes, cancer, high blood pressure, HIV, hepatitis and more.
HIV clinics could lose over $100 million each year—notably those serving Black, brown, queer and Southern communities.
The availability of multiple, low-cost generic versions of PrEP should be good news for access. But will it be?
Several formulations of generic Truvada are now available at a lower cost.
Plus, nearly a third of people already taking Truvada for PrEP switched to the new combination pill.
An HIV prevention roundup
“All insurers failing to offer PrEP without cost sharing beginning in January 2021 are clearly not following the law.”
Globally, a child contracts HIV every 100 seconds. A new, affordable treatment is available, but the COVID-19 pandemic hinders access.
Teva’s new version of TDF and emtricitabine doesn’t offer much of a price break, but that could come next spring.
A low-cost generic version of Truvada as PrEP will hit the market September 30.
You have been inactive for 60 minutes and will be logged out in . Any updates not saved will be lost.
Click here to log back in.